Russell J. Wiese

机构：Eli Lilly (United States) · ORCID：0009-0007-6705-7545

发表论文 51 篇 · 总被引 3594 次 · h-index 17

代表论文

• Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial (2021 · The Lancet · 被引 669)
• Mitogen-activated Protein Kinase Kinase Inhibition Does Not Block the Stimulation of Glucose Utilization by Insulin (1995 · Journal of Biological Chemistry · 被引 400)
• Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis (2022 · Nature Medicine · 被引 346)
• Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial (2022 · The Lancet Diabetes & Endocrinology · 被引 301)
• The Cardiac Tissue-Restricted Homeobox Protein Csx/Nkx2.5 Physically Associates with the Zinc Finger Protein GATA4 and Cooperatively Activates Atrial Natriuretic Factor Gene Expression (1998 · Molecular and Cellular Biology · 被引 275)
• The Transcription Factor GATA4 Is Activated by Extracellular Signal-Regulated Kinase 1- and 2-Mediated Phosphorylation of Serine 105 in Cardiomyocytes (2001 · Molecular and Cellular Biology · 被引 270)